Lucent Diagnostics News Today

Lucent Diagnostics, a diagnostics brand of Quanterix Corporation announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimers disease -...

Agreement provides Quanterix a license to extensively studied p-Tau 217 antibodies to enable global access to plasma-based testing for Alzheimer's Disease research and diagnostics Quanterix Corporation (NASDAQ:QTRX),

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment ...

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.

Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD).

BILLERICA, Mass.--(BUSINESS WIRE)--Jul 6, 2023--

Test will play an important role in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer’s disease